Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information

Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information

March 16, 2018

Combining germline and somatic information provides more comprehensive view from diagnosis through treatment

Detailed genomic characterization of tumors rapidly enhancing drug development through biomarker-driven clinical trials

Invitae Corporation (NYSE: NVTA) and KEW, Inc. today announced a collaboration to develop comprehensive genomic profiling solutions for sequencing tumor DNA on Invitae’s next generation sequencing (NGS) platform. By adding KEW’s somatic mutation detection capabilities to Invitae’s extensive portfolio of diagnostic genetic testing panels for hereditary cancers, Invitae will be able to help clinicians ...

Read more


Invitae expands existing credit facility to provide up to $40.0 million in available growth capital

Invitae expands existing credit facility to provide up to $40.0 million in available growth capital

February 27, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it has reached an agreement with Oxford Finance, LLC to expand its existing loan and security agreement by $20.0 million, bringing the total remaining capital available under the agreement to $40.0 million. This increase in net borrowing ability provides additional financial flexibility in 2018 as Invitae seeks to grow the size and scope of its genome network.

Invitae received gross proceeds of $40 ...

Read more


Invitae to present at the Cowen and Company 38th Annual Health Care Conference

Invitae to present at the Cowen and Company 38th Annual Health Care Conference

February 26, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Monday, March 12, 2018 at 11:20 a.m. Eastern / 8:20 a.m. Pacific in Boston, Massachusetts.

A live webcast of the presentation may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of ...

Read more


Invitae reports over 150% volume and over 170% revenue growth for 2017

Invitae reports over 150% volume and over 170% revenue growth for 2017

February 12, 2018

Annual test volume exceeds high end of guidance

Robust test volume and revenue growth expected to continue in 2018 and beyond

Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the fourth quarter and full year ended December 31, 2017.

“Over the past year, we have made significant strategic investments that we believe uniquely position our ...

Read more


Invitae to participate in two upcoming investor conferences, including the 2018 BIO CEO & Investor Conference and Leerink Partners 7th Annual Global Healthcare Conference

Invitae to participate in two upcoming investor conferences, including the 2018 BIO CEO & Investor Conference and Leerink Partners 7th Annual Global Healthcare Conference

January 31, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will participate in two upcoming investor conferences being held in New York City.

Sean George will present at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 10:00 a.m. Eastern / 7:00 a.m. Pacific. Additionally, Sean George will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare ...

Read more


Invitae to announce fourth quarter and year-end 2017 financial results on February 12, 2018

Invitae to announce fourth quarter and year-end 2017 financial results on February 12, 2018

January 29, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its fourth quarter and year-end 2017 financial results on Monday, February 12, 2018 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.

The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and ...

Read more


Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018

Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018

January 08, 2018

127% increase in annual test volume exceeds high end of projected range

136% increase in full-year 2017 revenue in line with guidance

Anticipates continued, robust test volume and revenue growth in 2018 on strength of newly expanded business

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced preliminary full-year 2017 results that demonstrate continued strong momentum, with volume and revenue more than doubling compared to 2016 results. Preliminary financial results for 2017 include:

  • 127% year-over-year growth ...

Read more


Invitae to present at the 36th Annual J.P. Morgan Healthcare Conference

Invitae to present at the 36th Annual J.P. Morgan Healthcare Conference

December 20, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 2:00 p.m. Pacific at The Westin St. Francis in San Francisco.

The live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will ...

Read more


Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their Families

Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their Families

December 05, 2017

Invitae to present findings at 2017 San Antonio Breast Cancer Symposium

Research presented today by Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, shows how clinicians are using genetic testing beyond BRCA1 and BRCA2 to guide treatment and screening decisions for hereditary breast and ovarian cancer (HBOC) patients and their families. The data are being presented at the 2017 San Antonio Breast Cancer Symposium.

Earlier research from Invitae published in the October issue of Annals of ...

Read more


Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services

Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services

November 15, 2017

Complements recent acquisition of Good Start Genetics to establish comprehensive service for IVF clinics, ob/gyns

Entry into family health genetics creates integrated platform to support use of genetics in mainstream medical care

Results of warrant exchange offer announced

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has completed its acquisition of CombiMatrix, which specializes in providing genetic information for prenatal diagnosis, miscarriage analysis and diagnosis of pediatric developmental disorders, establishing Invitae as ...

Read more